← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab and hyaluronidase-nvhy · Bristol Myers Squibb

FDA approvalNew formulationMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with specified solid tumor indications already approved for IV nivolumab, as monotherapy, maintenance after IV nivolumab plus ipilimumab, or with designated chemotherapy or cabozantinib. Concurrent IV ipilimumab is not part of this approval.

LAMPGEN ANALYSIS

Why it matters

The subcutaneous formulation offers another route across multiple tumor types. Its supporting pharmacokinetic comparison was conducted in renal cell carcinoma.

What research teams should watch

Update route-specific orders and chair planning; verify the complete regimen before switching a patient from IV nivolumab.

PRIMARY RECORDS

Sources